Rapid, cost-effective salmonella PCR assay for chocolate detection on fluxergy platform
Introducing a fast, cost-effective PCR assay on the Fluxergy platform to detect Salmonella in chocolate, achieving sensitivity of 1 CFU per 375g in under 8 hours. This solution offers a significant reduction in testing time and cost compared to traditional methods.
Overview
The Fluxergy platform presents a groundbreaking solution for the rapid and cost-effective detection of Salmonella spp., including atypical subspecies, in chocolate matrices. This innovative PCR assay leverages Fluxergy's multimodal platform to achieve a detection limit of 1 CFU per 375g within just 8 hours, providing a substantial improvement over traditional methods that require lengthy pre-enrichment steps. The platform is designed to offer a cost-effective alternative with a target cost per test of under 50€, making it an attractive option for chocolate manufacturers seeking efficient and reliable quality control measures.
Technical specifications
Key features:
- Utilizes a multiplex PCR cartridge capable of targeting up to 6 different markers, integrated with internal controls in each reaction.
- Optimized for complex sample matrices like chocolate, which contain high fat and low water activity.
- Incorporates a refined sample preparation process, including homogenization, pre-enrichment, and bacterial concentration to reduce testing time.
- Features an integrated nucleic acid extraction system employing a magnetic bead method, enhancing lysis and purification for Gram-negative bacteria.
- Designed to meet ISO6579 standards, ensuring high reliability and accuracy.
Technology readiness level
The technology is currently at TRL 6, indicating that it has been tested in a relevant environment and is approaching commercialization. The next steps include further validation and optimization to fully integrate the assay into the Fluxergy platform, ensuring it meets the industry's rigorous standards and requirements.
About Fluxergy Inc
Fluxergy is a biotechnology company based in Irvine, California, that provides a multimodal diagnostic platform designed for point-of-care testing. The company’s system integrates multiple diagnostic technologies—including molecular (PCR), immunochemistry, cytometry, and electrochemistry—onto a single, compact analyzer. Its proprietary test cards utilize a modular microfluidic chip design, allowing for versatility in testing applications while remaining cost-effective through automated, high-throughput manufacturing processes. The platform also includes FluxergyWorks, a middleware software solution that enables data management and seamless integration with Electronic Medical Record (EMR) and Laboratory Information Management (LIMS) systems.
By consolidating several diagnostic modalities into one platform, Fluxergy aims to deliver fast, accurate, and affordable health insights directly at the point of care. This approach is intended to empower clinicians and caregivers to make informed, real-time patient care decisions, helping to bridge the gap between complex laboratory testing and on-site clinical needs. Furthermore, the company offers its platform as an open OEM solution, partnering with developers to enable them to bring new assays to market more efficiently. With a 70,000-square-foot facility dedicated to technology innovation and microfluidic manufacturing, Fluxergy emphasizes scalable production capabilities to meet diagnostic demand.
delivered to your inbox.